Program
sacituzumab govitecan
Also written as “Sacituzumab Govitecan-hziy”, “Sacituzumab Govitecan” and “Sacituzumab Govitecan-hziy (SG)”.
Its studies are mostly in Triple Negative Breast Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Transitional Cell · Neoplasm Metastasis, led by 2 companies.
Drug pageSacituzumab govitecan: every studyAll 102 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 2317 open or running | phase 4since Mar 19, 2020 | Jun 26, 2012 | Dec 2026phase 1 · NCT04617522 |
| Merck | 11 open or running | phase 3since Nov 2, 2022 | Nov 2, 2022 | Jan 12, 2027phase 3 · NCT05609968 |
Also a collaborator on its studies: Pfizer, Merck KGaA, Darmstadt, Germany and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named sacituzumab govitecanINNProposed as its International Nonproprietary Name in WHO's List 113
- Nov 2, 2022First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05609968 · 614 enrolled · United States, Australia, Brazil and more
Ahead
- Jan 12, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05609968
TargetBeta
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab tirumotecan | Merck | phase 3 | 50 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05609968Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jan 12, 2027 | 614 |
How it is read
Names in the registry
- “Sacituzumab Govitecan-hziy”, 12 entries
- “Sacituzumab Govitecan”, 4 entries
- “Sacituzumab Govitecan-hziy (SG)”, 4 entries
- “Sacituzumab govitecan-hziy (SG)”, 2 entries
- “Sacituzumab Govitecan (SG)”, 2 entries
Conditions, from the studies’ own filings
- Triple Negative Breast Neoplasms, 7 studies
- Breast Neoplasms, 5 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Carcinoma, Transitional Cell, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.